



Recipient country annual review report

# CAMBODIA

## 2010

### Background

Soil-transmitted helminths (STH) are endemic throughout Cambodia. Mebendazole donated by J&J has been distributed in all 24 provinces during six mass drug administration (MDA) campaigns between 2008 and 2010.

### Country Program Highlights 2010:

- With the support of J&J, HKI and the Ministries of Health and Education collaborated to produce hygiene education curriculum and materials which will be used to train teachers on hygiene and sanitation education methods for the classroom.
- Production of “School Deworming Day in Cambodia,” a video telling the story of how CWW works with Helen Keller International (HKI) and the Ministries of Health and Education in Cambodia to break the cycle of reinfection.

[www.youtube.com/watch?v=0nC-394mvyI](http://www.youtube.com/watch?v=0nC-394mvyI)



### Basic Country and STH Prevalence Data

Population data <sup>1</sup>	
Total Population	13,542,410
Total SAC population (5-14 years)	2,752,088
Primary school enrollment rate (2008) <sup>2</sup>	
Male	90%
Female	87%
Water and sanitation indicators (2008) <sup>2</sup>	
% population using improved drinking water sources	61%
% population using improved sanitation facilities	29%
Target population for STH treatment	
STH Prevalence (2000-2002) <sup>3</sup>	9.6 - 81%
SAC population requiring STH treatment <sup>1</sup>	2,752,088
Total number of provinces	24
Number of provinces requiring STH treatment	24

<sup>1</sup> Source: Data received from School Health Department under the Ministry of Education, Youth and Sports.

<sup>2</sup> Source: The World Bank, <http://data.worldbank.org/country>.

<sup>3</sup> Source: Baseline data from 2007 initial application for mebendazole. Parasitological surveys were conducted in 2006 in six provinces and again in 2007 and 2008.



# CAMBODIA

## 2010 Annual Summary Report

### 2010 Drug Inventory

# tablets available at start of 2010 (a)	# tablets received (b)	# tablets distributed (SAC + Community*) (c)	# tablets in inventory (a + b) - c
3,408,220	11,601,000 <sup>^</sup>	5,992,246*	9,016,974

<sup>^</sup>Due to the order generation and commitment schedule from J&J's production facilities, the order quantity for the entire annual requirement was generated, confirmed, and shipped in September 2010. This shipment was larger than needed for 2010 and excess mebendazole will be used in 2011 and 2012. The variance from 2012 mebendazole reapplication reports of 6 million tablets received is due to adjustment for calculation errors.

\*Includes 5,322,653 tablets provided to school-age children, plus 669,593 tablets provided as incentive to community.

The variance from 2012 mebendazole reapplication report includes an additional 9,845 community members not added to the original total.

### 2011 Forecast

# tablets available at start of 2011 (a)	# tablets to be distributed for 2011 (b)	# tablets shipped for 2011 (c)	# tablets to be shipped in 2011 for 2012 (d)	Estimated inventory at end of 2011 (a + c + d) - b
9,016,974	6,000,000 <sup>^</sup>	0	2,376,000*	5,392,974

<sup>^</sup>Request for treatment in the 2011 mebendazole reapplication report was 5.5 million. Upon review of the report it was determined that 6 million treatments were needed.

\*Mebendazole is scheduled to be shipped when it becomes available from J&J.

### 2012 Application

Estimated # tablets available at start of 2012 (a)	# tablets requested for 2012 (b)	# treatments recommended for 2012 (c)	# tablets to be shipped for 2012 (d)	Estimated Inventory at end of 2012 (a + c + d) - b
5,392,974	5,500,000	6,000,000 <sup>^</sup>	609,000*	1,974

<sup>^</sup>Request for treatment in the 2012 mebendazole reapplication report was 5.5 million. Upon review of the report it was determined that 6 million treatments were needed.

\*Additional tablets needed for 2012 that were not shipped in 2011.